Barclays reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Thursday morning, AnalystRatings.com reports. Barclays currently has a $182.00 target price on the specialty pharmaceutical company’s stock.
A number of other research analysts have also weighed in on the company. BidaskClub lowered Jazz Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, October 11th. TheStreet lowered Jazz Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, October 18th. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Wednesday, August 14th. Evercore ISI reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Monday, August 12th. Finally, Zacks Investment Research lowered Jazz Pharmaceuticals from a buy rating to a hold rating and set a $138.00 target price on the stock. in a report on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $165.71.
JAZZ traded up $4.18 during midday trading on Thursday, reaching $130.14. 747,500 shares of the company were exchanged, compared to its average volume of 551,936. The stock has a market capitalization of $7.24 billion, a P/E ratio of 10.63, a PEG ratio of 1.57 and a beta of 1.09. Jazz Pharmaceuticals has a one year low of $113.52 and a one year high of $154.44. The stock’s 50-day simple moving average is $124.77 and its 200 day simple moving average is $131.70. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71.
In related news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the completion of the sale, the chief executive officer now directly owns 311,855 shares in the company, valued at approximately $40,541,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Insiders have sold a total of 5,371 shares of company stock worth $730,575 over the last three months. 4.30% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MUFG Americas Holdings Corp bought a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $29,000. Condor Capital Management boosted its stake in Jazz Pharmaceuticals by 3.1% in the 3rd quarter. Condor Capital Management now owns 10,414 shares of the specialty pharmaceutical company’s stock valued at $1,334,000 after purchasing an additional 318 shares during the period. Systematic Financial Management LP boosted its stake in Jazz Pharmaceuticals by 0.8% in the 3rd quarter. Systematic Financial Management LP now owns 106,278 shares of the specialty pharmaceutical company’s stock valued at $13,618,000 after purchasing an additional 794 shares during the period. Balasa Dinverno & Foltz LLC bought a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $408,000. Finally, Means Investment CO. Inc. boosted its stake in Jazz Pharmaceuticals by 25.6% in the 3rd quarter. Means Investment CO. Inc. now owns 3,190 shares of the specialty pharmaceutical company’s stock valued at $410,000 after purchasing an additional 650 shares during the period. Institutional investors and hedge funds own 87.71% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: What is meant by holder of record?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.